Related coverage linked through entity extraction aliases.
Aug 13, 2026
A 19-month-old girl with influenza A (H1N1)-associated acute necrotizing encephalitis made a complete neurological recovery despite a severity score of 6. Multimodal immunomodulatory therapy including IVIG, corticosteroids, anakinra, and plasma exchange led to rapid decline in blood cytokine levels. The case underscores early recognition and targeted treatment in young children.
Apr 29, 2026
Three FcRn inhibitors are approved for generalized myasthenia gravis, with a head-to-head trial of efgartigimod and nipocalimab underway. Emerging therapies including telitacicept, gefurulimab, and CAR-T cell therapy (KYV-101) show promise, while Immunovant's batoclimab failed TED trials.
Mar 06, 2026
The FDA has accepted Hansa Biopharma's Biologics License Application for imlifidase, a desensitization treatment for highly sensitized adult kidney transplant patients with positive crossmatch against deceased donors, with a PDUFA date of December 19, 2026.
Feb 26, 2026
CAR T-cell therapy is delivering high remission rates for multiple myeloma patients, with improved handoff communication reducing infection risks. FDA-approved BCMA-targeting products show response rates from 72% to 98% in heavily pretreated patients.
